Tensive secures €20 million EIB loan for breast
MedTech startup Tensive has received a €20 million convertible loan from the European Investment Bank to fund the final development and launch of its
Milan-based medical device startup Tensive has secured a €20 million convertible loan from the European Investment Bank. The funds, part of a €40 million financing plan, will advance the clinical development, regulatory approval, and commercial launch of its REGENERA bioresorbable scaffold for breast reconstruction.
"The EIB has examined our clinical evidence and our regulatory file in detail and has committed €20 million to enable us to take REGENERA from our recently reported positive key clinical results to a product in the hands of European surgeons," said Sanjay Kakkar, MD, Chief Executive Officer of Tensive. He stated the loan anchors the company's ongoing equity fundraising.
The REGENERA Technology
Founded in 2012, Tensive develops bioresorbable, biomimetic polymeric scaffolds. The REGENERA product is a sponge-like material designed to be placed during a lumpectomy procedure. It is gradually absorbed by the body and replaced by the patient's own natural tissue, aiming to restore the breast's original shape and feel.
The company says the material adapts to the surgical cavity without manual adjustment, offering a fast option for surgeons. Because it is absorbed, it eliminates the need for future surgery to remove an implant. The implant is also clearly visible on diagnostic imaging, which the company says allows for more precise radiotherapy targeting and follow-up monitoring.
Financing and Market Context
The EIB loan is structured in two tranches: €8 million initially and a further €12 million later, with a 20-year maturity from each drawdown date. This facility covers half the capital needed to complete development and launch in the EU and U.S. Tensive reports it is in active discussions with institutional and strategic investors to secure the remaining €20 million.
This financing occurs alongside other significant investments in European medical technology in 2026. According to the source, EU-Startups has reported approximately €151 million in related funding announcements.
| Company | Location | Sector | Amount |
|---|---|---|---|
| Xeltis | Dutch-US | Vascular implants | €20.5 million |
| FineHeart | France | Cardiac devices | €83 million |
| SamanTree Medical | Belgium | Surgical imaging | €20 million |
| ScreenPoint Medical | Not specified | Breast-cancer detection | €13.6 million |
| Wearable Robotics | Pisa, Italy | Rehabilitation robotics | €5 million |
| Cellply | Bologna, Italy | Cancer therapy tools | €7.15 million |
"Supporting European innovation in health, and in women’s health in particular, is central to the EIB Group’s mission," added EIB Vice President Gelsomina Vigliotti.
Clinical Progress and Timeline
Recent clinical data supports the product's development. On July 28, 2026, Tensive reported 12-month follow-up data from its key trial involving 94 patients. The company recorded good-to-excellent cosmetic outcomes in 94.2% of evaluable cases at twelve months. Patient-reported satisfaction scores showed significant improvement, and the scaffold caused no interference with oncologic imaging.
Separately, five-year follow-up data from an earlier study indicated persistent volume replacement and gradual resorption of the scaffold with no capsule formation. Tensive anticipates achieving EU regulatory approval for REGENERA as early as 2027.
CEO Kakkar concluded the loan brings the company closer to offering what he calls the first natural, lasting solution for women with limited reconstruction options after a lumpectomy.
